-+ 0.00%
-+ 0.00%
-+ 0.00%

Tenax signs oral levosimendan supply deal with Orion

PUBT·06/30/2026 20:32:05
Listen to the news
Tenax signs oral levosimendan supply deal with Orion
  • Tenax signed a supply agreement with Orion on June 29, 2026 for oral levosimendan manufacturing and supply for development and potential commercialization.
  • Contract includes cost-sharing to scale up Orion’s manufacturing capabilities.
  • Initial term runs five years from first delivery, with automatic three-year renewals unless either party gives 24 months’ notice.
  • Sixth amendment to the license agreement extends the US regulatory-approval milestone deadline to Dec. 31, 2035.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenax Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-290661), on June 30, 2026, and is solely responsible for the information contained therein.